IN THE CLAIMS

Please withdraw Claims 4, 8, 9,

Please cancel Claims 15, 17, 20, 22, 24, 25, 28, 33-42, 47 and 49 without prejudice to minimize patenting expenses.

Please amend Claim 2, 5, 6, 10, 11, 12, 13, 14, 16, 18, 19, 21, 23, 26, 27, 29, 31, 32, 43-46, 48.

Amendments to the Claims

1. (Original). A compound having a formula I,

$$Z \xrightarrow{A_3} Y \xrightarrow{R^1} A_2 \xrightarrow{(R^3)_r} E_1 \xrightarrow{E_2} A_1 \xrightarrow{Q} E_3 \xrightarrow{E_4} E_5$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ and A₃ are independently: CH₂, O or S;

 E_1 , E_2 , E_3 , E_4 and E_5 are each CH or substituted carbon bearing A_2 and R^3 ; or at least one of E_1 , E_2 , E_3 , E_4 and E_5 is nitrogen and each of others being CH or substituted carbon bearing A_2 and R^3 ;

Q is: $-C(O)OR^6$, or R^{6A} ;

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

- Z is: a) aryl;
 - b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

Docket No. X-15998

- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R¹ and R² are each independently:

hydrogen,

haloalkyl,

 C_1 - C_6 alkyl,

 $(CH_2)_nC_3$ - C_8 cycloalkyl, or

R¹ and R² form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R¹ and R² is alkyl or cycloalkyl, and;

R³ is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

 C_1 - C_6 alkyl,

C₁-C₆ alkoxy or

C₃-C₈ cycloalkyl;

R⁴ and R⁵ are each independently: hydrogen or C₁-C₆ alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkoxy,

(CH₂)_nC₃-C₈ cycloalkyl,

 $C(O)R^9$,

 $C(O)OR^9$,

 $C(=NOR^8)R^9$,

CR⁸(OH)R⁹,

 $C[=C(R^8)_2]R^9$,

OR⁹,

SR⁹ or

 $S(O)_pR^9$;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

2. (Currently Amended). The compound of Claim 1, wherein the compound having a is represented by a compound of formula II,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1 \qquad R^2 \qquad (R^3)_r} A_1 \xrightarrow{Q} A_2 \xrightarrow{R^4 \qquad R^5}$$

II

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 is: a bond, CH_2 , O or S, and wherein A_1 and R^4 or A_1 and R^5 together being a 3- to 6-

membered carbocyclyl when A₁ is a carbon;

 A_2 is: O or S or CH_2 ;

Q is: $-C(O)OR^6$, or R^{6A} ;

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;

b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

Docket No. X-15998

- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

```
n is: 1, 2, 3, 4, 5 or 6
p is: 1 or 2;
```

r is: 1, 2, 3, or 4;

R¹ and R² are each independently:

hydrogen,

haloalkyl,

C₁-C₆ alkyl,

 $(CH_2)_nC_3$ - C_8 cycloalkyl, or

 R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

```
R<sup>3</sup> is: hydrogen,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
C<sub>1</sub>-C<sub>6</sub> alkyl,
C<sub>1</sub>-C<sub>6</sub> eycloalkyl;
```

 R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, $(CH_2)_nC_3$ - C_8 cycloalkyl, $C(O)R^9$, $C(O)OR^9$, $C(=NOR^8)R^9$, CR8(OH)R9, $C[=C(R^8)_2]R^9$, OR⁹, SR⁹ or

 $S(O)_pR^9$;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

3. (Original). The compound of Claim 2, wherein Z is optionally substituted phenyl or naphthyl, furanyl, imidazolyl, indolyl, oxazolyl, isoxazolyl, pyridyl, pyrrolyl, thiazolyl, thiophenyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, quinolinyl, isoquinolinyl or a structural formula selected from following:

$$\begin{array}{c|c} \hline c \\ \hline T \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline f \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

$$T \\ \hline \begin{array}{c|c} \hline \\ g \\ \hline \end{array}$$

wherein T is:

a bond, $-(CH_2)_qO$ -, $-O(CH_2)_q$ -, $-C(O)(CH_2)_q$ -, $-(CH_2)_qC(O)$ -, $-(CH_2)_qS$ -, $-S(CH_2)_q$ -, $S[O]_p$, $-(C_1-C_3 \text{ alkyl})$ -, $-(CH_2)_qC(=CH_2)$ -, $-C(=CH_2)(CH_2)_q$ -, $-(CH_2)_qC(=NOH)$ -, $-C(=NOH)(CH_2)_q$ -, $-(CH_2)_qC(=NOCH_3)$ -, $-C(=NOCH_3)(CH_2)_q$ -, $-CH(OH)(CH_2)_q$ -, or $-(CH_2)_qCH(OH)$ -,

q is: 0, 1, 2 or 3; and

rings b to l are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

4. (Withdrawn) The compound of Claim 2, wherein the compound having a structural formula III,

$$Z \xrightarrow[CH_2]_m \xrightarrow{A_1} \xrightarrow{COOR^6}$$

$$III$$

5. (Currently Amended). The compound of Claim 4 Claim 2, wherein the compound having a is represented by structural formula IV,

$$R^{1}$$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl;

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) -S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

6. (Currently Amended). The compound of Claim 5, wherein the compound having a is represented by structural formula V,

$$R^1$$
 $COOH$
 $COOH$
 C
 C
 C
 C

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R¹ is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, methyl, ethyl, isopropyl, N(CH₃)₂, S(O)₂CH₃, methoxy and cyclopropyl.

7. (Original). The compound of Claim 6, wherein the compound is represented by a structural formula VI,

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. (Withdrawn) The compound of Claim 2, wherein the compound having a structural formula VII,

$$Z \sim O$$
 $(CH_2)_m \sim A_2$
 $A_1 \sim COOR^6$
VII

Z is:

$$\begin{array}{c|c} & & & \\ \hline b & & & \\ \hline & & \\ \hline \\ c & & \\ \hline \end{array} \qquad \text{or} \qquad \begin{array}{c|c} & & \\ \hline & & \\ \hline \\ k & \\ \hline \end{array}$$

A₁ and A₂ are respectively: bond and S; bond and O; CH₂ and S; or CH₂ and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl;

 R^3 is: hydrogen, halo or C_1 - C_6 alkyl;

 R^6 and R^9 are each independently: hydrogen or C_1 - C_6 alkyl;

T is: bond, -O-, -C(O)-, -S(O) –S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and rings b, c, k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

- 9. (Withdrawn) The compound of Claim 8, wherein R¹ is: methyl, ethyl or cyclopropyl; R³ is: methyl or ethyl; and rings b, c k and l are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, N(CH₃)₂, S(O)₂CH₃, methyl, ethyl, isopropyl, methoxy and cyclopropyl.
- 10. (Currently Amended). The compound of <u>Claim 4 Claim 2</u>, wherein the compound having a is represented by structural formula VIII,

$$R^3$$
 R^1
 $COOR^6$
 $CH_2)_m$
 A_2

VIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

R¹ is: C₁-C₃ alkyl; and

 R^3 is: hydrogen, halo or C_1 - C_6 alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$ -, $-C(=CH_2)$ -, -C(=NOH)- or -CH(OH)-; and ring b is optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

11. (Currently Amended). The compound of Claim 10, wherein the compound having a is represented by structural formula IX,

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: R^1 is C_1 - C_3 alkyl;

 R^3 is: hydrogen, halo or C_1 - C_4 alkyl;

ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C_1 - C_6 alkyl.

12. (Currently Amended). The compound of Claim 11, wherein the compound having a is represented by structural formula X,

$$CF_3$$
 CH_3
 CH_3
 $COOH$
 X

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. (Currently Amended). The compound of Claim 11, wherein the compound having a is represented by structural formula XI,

$$H_3C$$
 CH_3
 $COOH$
 XI

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

14. (Currently Amended). The compound of <u>Claim 4 Claim 2</u>, wherein the compound <u>having a is represented by structural formula XII</u>,

$$R^3$$
 R^1
 R^4
 R^5
 R^4
 R^5

XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁴, R⁵, R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

15. (Canceled)

16. (Currently Amended). The compound of Claim 2, wherein the compound having a is represented by structural formula XIII,

$$Z \underbrace{ \begin{pmatrix} (R^3)_r \\ R^2 \\ (CH_2)_m \end{pmatrix}}_{A_2} \underbrace{ \begin{pmatrix} (R^3)_r \\ A_1 \\ R^4 \end{pmatrix}}_{A_2} \underbrace{ \begin{pmatrix} (R^3)_r \\ R^4 \end{pmatrix}}_{COOR^6}$$

XIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein m is 1, 2, 3, or 4.

17. (Canceled).

18. (Currently Amended). The compound of <u>Claim 17 Claim 16</u>, wherein the compound <u>having a is represented by structural formula XV</u>,

$$R^2$$
 $COOH$
 $COOH$

XV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R² is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, N(CH₃)₂, S(O)₂CH₃, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. (Currently Amended). The compound of Claim 2, wherein the compound having a is represented by structural formula XVI,

$$Z \xrightarrow{O \qquad Y \qquad A_2} A_1 \xrightarrow{COOR^6}$$

XVI

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein Y is a branched alkyl or C_3 - C_6 cycloalkyl.

- 20. (Canceled).
- 21. (Currently Amended). The compound of <u>Claim 19</u>, wherein the compound having a structural formula XVIII,

COOH
$$COOH$$

$$COOH$$

$$COOH$$

XVIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R³ is: methyl or ethyl;

 R^{9a} and R^{9b} are each independently hydrogen, methyl or ethyl, wherein at least one of R^{9a} and R^{9b} being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

22. (Canceled).

23. (Currently Amended). The compound of Claim 1, wherein the compound having a is a compound of formula XX,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1 \quad R^2 \quad (R^3)_r} A_1 \xrightarrow{Q} XX$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

 A_2 is: O or S or CH_2 ;

Q is: $-C(O)OR^6$, or R^{6A} ;

Y is: a bond, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl;

Z is: a) aryl;

- b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

```
R^1 and R^2 are each independently: hydrogen, \\ haloalkyl, \\ C_1\text{-}C_6 \text{ alkyl}, \\ (CH_2)_nC_3\text{-}C_8 \text{ cycloalkyl, or} \\ R^1 \text{ and } R^2 \text{ form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of } R^1 \text{ and } R^2 \text{ is alkyl or cycloalkyl, and;}
```

```
R<sup>3</sup> is: hydrogen,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
C<sub>1</sub>-C<sub>6</sub> alkyl,
C<sub>1</sub>-C<sub>6</sub> alkoxy, or
C<sub>3</sub>-C<sub>8</sub> cycloalkyl;
```

 R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, C₁-C₆ alkyl, C_1 - C_6 alkoxy, $(CH_2)_nC_3$ - C_8 cycloalkyl, $C(O)R^9$, $C(O)OR^9$, $C(=NOR^8)R^9$, CR8(OH)R9, $C[=C(R^8)_2]R^9$, OR⁹, SR⁹ or

 R^8 is: hydrogen or C_1 - C_6 alkyl; and

 $S(O)_pR^9$;

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

- 24. (Canceled).
- 25. (Canceled).
- 26. (Currently Amended). The compound of Claim 25 Claim 23, wherein the compound having a is a compound of structural formula XXII,

$$R^1$$
 $COOH$
 $COOH$
 $COOH$
 $COOH$
 $COOH$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R¹ is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. (Currently Amended). The compound of Claim 1, wherein the compound having a is a compound of structural formula XXIII,

$$R^{1}$$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$
 $COOR^{6}$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

 R^1 is: C_1 - C_3 alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) -S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

- 28. (Canceled).
- 29. (Currently Amended). A compound of Claim 1 selected from the group consisting of:

No.	Structure	Name
1		3-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
)—о ,сн₃	2-methyl-phenyl}-
	H ₃ C 0	propionic acid
	H₃C OH	⊕
2 ·		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
)≕o сн₃	2-methyl-phenoxy}-
	H ₃ C O O O O O O O O O O O O O O O O O O O	acetic acid
3		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
- Y-		2-methyl-
	H ₃ C CH ₃	phenylsulfanyl}-acetic
	CH ₃ OH	acid
4		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	-0	2-methyl-
	H ₃ C CH ₃	phenylsulfanyl}-acetic
	CH ₃ O	acid
	ОН	
5		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-
	> -0	butylsulfanyl]-2-methyl-
	H_3C CH_3	phenoxy}-acetic acid
	s—s—	
	H ₃ C CH	

No.	Structure	<u>Name</u>
6		3-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-
	CH₃	butylsulfanyl]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	H ₃ C	
	у ОН	
7		2-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	H ₃ C, CH ₃ O	2-methyl-phenoxy}-2-
		methyl-propionic acid
	CH ₃ H ₃ C CH ₃	
8		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
		phenoxy}-acetic acid
	H ₃ C 0	phonony, access acid
	OH OH	
	H ₃ C	
9		3-{4-[3-(2-Benzoyl-4-
		isopropyl-phenoxy)-
	H ₃ C, CH ₃	butoxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	CH ₃ OH	
10	Chiral	3-{4-[3-(2-Benzoyl-4-
		cyclopropyl-phenoxy)-
	CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH ₃	
	OH	

No.	Structure	Name
11		3-{4-[3-(2-Benzoyl-4-
		trifluoromethyl-
	F, CH ₃	phenoxy)-butoxy]-2-
	F O	methyl-phenyl}-
	CH₃ OH	propionic acid
12		2 [4 [2 (2 Pangoyl 4
12		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	∠CH₃	butoxy]-2-methyl-
	CI—OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	phenyl}-propionic acid
	CH₃ OH	
13		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	ÇCH₃	butoxy]-2-methyl-
	CI—OH3	phenyl}-propionic acid
14	Chiral	3-{4-[3-(2-Benzoyl-4-
		methoxy-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	H ₃ C-O-	phenyl}-propionic acid
	CH₃ OH	
15	Chiral	3-{4-[3-(2-Benzoyl-4-
		fluoro-phenoxy)-
·)	butoxy]-2-methyl-
	F—CH ₃	phenyl}-propionic acid
	CH ₃	*
	On .	

No.	Structure	Name
16	Chiral	3-{4-[3-(2-Benzoyl-4-
·		isopropyl-phenoxy)-
	H ₃ C, CH ₃	butoxy]-2-methyl-
+	H ₃ C O	phenyl}-propionic acid
	CH ₃	
		*
17		{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
) =0	butoxy]-2-methyl-
	CI CH ₃	phenylsulfanyl}-acetic
	CH ₃ OH	acid
18	2	3-(4-{3-[4-Ethyl-2-
10		
		(hydroxy-phenyl-
	H³C CH³	methyl)-phenoxy]- butoxy}-2-methyl-
-		phenyl)-propionic acid
	сн, Он	phenyly-propionic acid
19		3-(4-{3-[4-Ethyl-2-
		(hydroxyimino-phenyl-
	N-OH CH ₃	methyl)-phenoxy]-
	H ₃ C	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
20		3-(4-{3-[4-Ethyl-2-
		(methoxyimino-phenyl-
	H,C /= N−O−CH ₃ CH ₃	methyl)-phenoxy]-
	H ₃ C CH ₃	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
21	H ₃ C CH ₃ Chiral	3-{4-[3-(4-Isopropyl-2-
	H ₃ C	phenoxy-phenoxy)-
	O CH ₃ OH	butoxy]-2-methyl-
		phenyl}-propionic acid
L		

No.	Structure	Name
22	Chiral	{4-[3-(4-Isopropyl-2-
		phenoxy-phenoxy)-
	H³C CH³	butoxy]-2-methyl-
	H ₃ C	phenylsulfanyl}-acetic
	H₃Č	acid
22	OH H ₃ C、_CH ₃	2 (4 [2 (4 E4 1 2
23	H₃C CH₃	3-{4-[3-(4-Ethyl-2-
	H³C′ ← CH³	isobutyryl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
	ОН	y- 8-
24	\triangleleft	3-{4-[3-(2-
	<u> </u>	Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	ĊН ₃ ОН	propionic acid
25	1	3-{4-[3-(2-
		Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	СН ₃ ОН	propionic acid
26		3-{4-[3-(2-
		Cyclopentanecarbonyl-4-
		ethyl-phenoxy)-butoxy]-
	H ₃ C CH ₃	2-methyl-phenyl}-
	H ₃ C O	propionic acid
	ОН	Ži.

No.	Structure	<u>Name</u>
.27	H₃C ✓ CH₃	2-{4-[3-(4-Ethyl-2-
•		isobutyryl-phenoxy)-
	H ₃ C OH	butoxy]-phenoxy}-2-
	CH ₃ H ₃ C CH ₃	methyl-propionic acid
28		2-{4-[3-(2-
*) =0	Cyclopropanecarbonyl-4-
	H ₃ C /	ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	CH ₃ H ₃ C CH ₃ OH	propionic acid
29	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	DO CH3 OH	butoxy]-2-methyl-
		phenyl}-propionic acid
		*
30		{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
*		phenylsulfanyl}-acetic
	™ ČH₃ ✓ ✓ OH	acid
31	Chiral	3-{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	CH₃	butoxy]-2-methyl-
	CI—()—O	phenyl}-propionic acid
	CH ₃	` · ·
	он	
32	Chiral	{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	о Сн₃	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	ĈH₃ OH	acid
L		L

No.	Structure	Name
33	Chiral	3-{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-
	OCH ₃	2-yloxy)-butoxy]-2-
		methyl-phenyl}-
	CH ₃	propionic acid
	On	
34	Chiral	{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-2-
	F CH ₃	methyl-phenylsulfanyl}-
	F N H ₃ C OH	acetic acid
35	Chiral	3-{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-
÷	6	yloxy)-butoxy]-2-
	CI—CH ₃	methyl-phenyl}-
		propionic acid
	ČH ₃ ОН	
36	Chiral	3-{4-[3-(5-Chloro-3-
	<u> </u>	phenoxy-pyridin-2-
	CH₃	yloxy)-butoxy]-2-ethyl-
	CI—	phenyl}-propionic acid
	CH ₃ OH	
37	Chiral	{4-[3-(5-Chloro-3-
	\ \(\)	phenoxy-pyridin-2-
.	,сн₃	yloxy)-butoxy]-2-
	CI—O—O—S—	methyl-phenylsulfanyl}-
	N H ₃ C OH	acetic acid
L		· · ·

No.	Structure	<u>Name</u>
38	F CH ₃ Chiral	3-{2-Methyl-4-[3-(3-
·		phenoxy-5-
	OH OH	trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-
	·	phenyl}-propionic acid
39	Chiral	3-{2-Ethyl-4-[3-(3-
٠.		phenoxy-5-
	F CH ₃	trifluoromethyl-pyridin-
	F O	2-yloxy)-butoxy]-
	F —N H ₃ C —O—OH	phenyl}-propionic acid
	**	
40	Chiral	3-{2-Ethyl-4-[3-(3-
		phenoxy-5-
	CH ₃	trifluoromethyl-pyridin-
	F O	2-yloxy)-butoxy]-
	F H ₃ C	phenyl}-propionic acid
	ОН	-
41	F O	3-{2-Methyl-4-[3-(3-
	F OH	phenoxy-5-
	F ✓ CH₃	trifluoromethyl-pyridin-
* .	F—————————————————————————————————————	2-yloxy)-propoxy]-
		phenyl}-propionic acid
	`OI	(trifluoroacetic acid salt)
42	_ <i>[</i>	3-{4-[3-(5-Chloro-3-
	F	phenoxy-pyridin-2-
	ОН	yloxy)-propoxy]-2-
		methyl-phenyl}-
	CI—CH ₃	propionic acid
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	· ·
	`OH	
Ll		

No.	Structure	<u>Name</u>
43		3-{4-[2-(5-Chloro-3-
		phenoxy-pyridin-2-
		ylamino)-ethoxy]-2-
·	$CI$ $N$ $CH_3$	methyl-phenyl}-
		propionic acid
	ОН	, , , , , , , , , , , , , , , , , , , ,
44	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	OH OH	propoxy]-2-methyl-
		phenyl}-propionic acid
15	Chiral	2 (2 ) (-1 -1 4 52 (6
45	Chirat	3-{2-Methyl-4-[3-(6-
		methyl-2-phenoxy-
. :	N=\ CH ₃	pyridin-3-yloxy)-
	H ₃ C — 0 — 0	butoxy]-phenyl}-
	н₃с он	propionic acid
46		3-{4-[3-(5-Ethyl-
		biphenyl-2-yloxy)-
	H₃C CH₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	ĈН ₃ ОН	promyry proprome acid
47	Chiral	3-{4-[3-(4-Ethyl-2-
	N CH	oxazol-2-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	ОН	phenyl}-propionic acid
	CH₃	
48	H ₃ C Chiral	3-{4-[3-(4-Ethyl-2-
		thiazol-4-yl-phenoxy)-
	N CH ₃	butoxy]-2-methyl-
	U _S OH	phenyl}-propionic acid
ļ 	·	promjij proprome deid

No.	Structure	<u>Name</u>
49.	Chiral	3-{4-[3-(4-Ethyl-2-
-	N	pyridin-2-yl-phenoxy)-
:	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C OH	phenyl}-propionic acid
50	Chiral	{4-[3-(4-Ethyl-2-pyridin-
	// γ N ÇH₃ Ω	2-yl-phenoxy)-butoxy]-
	H₃C OH	2-methyl-
		phenylsulfanyl}-acetic
	н₃ <b>ँ</b>	acid
51	ÇH ₃ Chiral	3-{2-Ethyl-4-[3-(4-ethyl-
	ОН	2-pyridin-2-yl-phenoxy)-
		butoxy]-phenyl}-
	CH ₃	propionic acid
52	Chiral	3-{4-[3-(4-Chloro-2-
-	>=n	pyridin-2-yl-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	OH /	* .
53	F CH ₃ O Chiral	3-{2-Methyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
·		trifluoromethyl-
		phenoxy)-butoxy]-
	ĈH₃	phenyl}-propionic acid
54	F H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	ĈH₃	phenyl}-propionic acid

No.	Structure	<u>Name</u>
55	Chiral	3-{4-[3-(4-Ethyl-2-
	) N	pyridin-3-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	ОН	
56	Chiral	3-{4-[3-(4-Chloro-2-
,	ÇH₃	pyridin-3-yl-phenoxy)-
		butoxy]-2-methyl-
		phenyl}-propionic acid
	ČH₃ OH	
57	Chiral	3-{4-[3-(4-Ethyl-2-
		pyridin-4-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	ОН	*
58	F Chiral	3-{2-Methyl-4-[3-(2-
	Б	pyridin-4-yl-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	СН ₃	phenyl}-propionic acid
59	F N H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-4-yl-4-
		trifluoromethyl-
:		phenoxy)-butoxy]-
	CH ₃	phenyl}-propionic acid
60	N-O CH ₃ O Chiral	3-{4-[3-(2-
·	CI	Benzo[d]isoxazol-3-yl-4-
		chloro-phenoxy)-
		butoxy]-2-methyl-
	ĈH₃	phenyl}-propionic acid

No.	Structure	Name
61		3-{4-[3-(2-Benzoyl-4-
•		ethyl-phenoxy)-butoxy]-
	CH ₃	2-methyl-phenyl}-
	H ₃ C 0	propionic acid
	H ₃ C OH	
62		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	)—о сн _з	2-methyl-phenoxy}-
	H ₃ C	acetic acid
	ОН	•
	CH ₃	
63		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	H ₃ C CH ₃	2-methyl-
9		phenylsulfanyl}-acetic
	CH₃ OH	·
64		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	H,C, CH ₃	2-methyl-
	H ₃ C CH ₃	phenylsulfanyl}-acetic
	CH ₃	acid
45	ОН	(4 [2 (2 Paneral 4
65		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-
		butylsulfanyl]-2-methyl-
-	H³C CH³	phenoxy}-acetic acid
		phonoxy;-accur acid
	H ₃ C OH	

No.	Structure	Name
66		3-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-
	O CH₃	butylsulfanyl]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	H ₃ C S O	
	ОН	
67		2-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	OСН ₃	2-methyl-phenoxy}-2-
	H ₃ C O	methyl-propionic acid
	CH ₃ H ₃ C CH ₃	
68	3.13	(4 52 (2 D 1 4
08		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	H ₃ C O	phenoxy}-acetic acid
	H ₃ C OH	. *
	-	1.0
69		3-{4-[3-(2-Benzoyl-4-
		isopropyl-phenoxy)-
	H ₃ C, CH ₃	butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	CH ₃	
70	Chiral	3-{4-[3-(2-Benzoyl-4-
		cyclopropyl-phenoxy)-
	)=o	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
	CH ₃	;
	ОН	

No.	Structure	Name
71		3-{4-[3-(2-Benzoyl-4-
		trifluoromethyl-
	<b>&gt;</b> 0	phenoxy)-butoxy]-2-
	F CH ₃	methyl-phenyl}-
. e.	F CH ₃	propionic acid
	ОН	
72		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	СН3	butoxy]-2-methyl-
	CI—O	phenyl}-propionic acid
	CH ₃	t,
	у ОН	
73		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
•	Сн³	butoxy]-2-methyl-
	CI—O	phenyl}-propionic acid
	CH ₃ OH	
74	Chiral	3-{4-[3-(2-Benzoyl-4-
'4		
		methoxy-phenoxy)-
	CH₃	butoxy]-2-methyl-
	H ₃ C-O-_O-_O	phenyl}-propionic acid
	CH ₃ OH	
75	Chiral	3-{4-[3-(2-Benzoyl-4-
		fluoro-phenoxy)-
		butoxy]-2-methyl-
	F—CH ₃	phenyl}-propionic acid
	CH ₃	* *
	ОН	
		L

isopropyl-pheno butoxyl-2-methy phenyl}-propior  77  Chir {4-[3-(2-Benzoy isopropyl-pheno butoxy]-2-methy phenylsulfanyl} acid  78  {4-[3-(2-Benzoy isopropyl-pheno butoxy]-2-methy phenylsulfanyl} acid  78  (4-[3-(2-Benzoy chloro-phenoxy butoxy]-2-methy phenylsulfanyl} acid  79  3-(4-{3-[4-Ethy (hydroxy-phenox butoxy}-2-methy butoxy}-2-methy butoxy}-2-methy butoxy}-2-methy butoxy}-2-methy butoxy}-2-methy	· .	Name	Structure	No.
This characteristics of the control	zoyl-4-	3-{4-[3-(2-Benzoyl-4-	Chiral	76
Phenyl}-propior  This table is the phenyl for the p	oxy)-	isopropyl-phenoxy)-		
Phenyl}-propior  Thir {4-[3-(2-Benzoy isopropyl-pheno butoxy]-2-methy phenylsulfanyl} acid  This characteristic content of the	yl-	butoxy]-2-methyl-	H.C CH.	
This Chir [4-[3-(2-Benzoy isopropyl-pheno butoxy]-2-methy phenylsulfanyl] acid  The Chir [4-[3-(2-Benzoy isopropyl-phenoxy) butoxy]-2-methy phenylsulfanyl] acid	nic acid	phenyl}-propionic acid		
77  Chir {4-[3-(2-Benzoy isopropyl-pheno butoxy]-2-methy phenylsulfanyl} acid  78  {4-[3-(2-Benzoy chloro-phenoxy) butoxy]-2-methy phenylsulfanyl} acid  79  H ₃ C  CH ₃ OH  3-(4-{3-[4-Ethy] (hydroxy-pheny methyl)-phenox butoxy}-2-methy phenylsulfanyl} acid	- 		ĊH. W	
isopropyl-pheno butoxy]-2-methy phenylsulfanyl} acid  78  {4-[3-(2-Benzoy chloro-phenoxy) butoxy]-2-methy phenylsulfanyl} acid  79  GH3  GH3  GH4  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-methy phenyl)-propion			On .	
H ₃ C  H ₃ C  CH ₃ butoxy]-2-methy phenylsulfanyl} acid  78  {4-[3-(2-Benzoy chloro-phenoxy) butoxy]-2-methy phenylsulfanyl} acid  79  GH ₃ C  CH ₃ OH  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-methy phenyl)-propion	yl-4-	{4-[3-(2-Benzoyl-4-	Chi	77
Phenylsulfanyl acid  78  \[ \begin{array}{c} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	oxy)-	isopropyl-phenoxy)-		
78  GH ₃ CH ₃ OH  Acid  [4-[3-(2-Benzoy chloro-phenoxy) butoxy]-2-methy phenylsulfanyl} acid  79  GH ₃ OH  GH ₃ CH ₃ OH  CH  CH  CH  CH  CH  CH  CH  CH  CH	yl-	butoxy]-2-methyl-	о,сн₃	
78  {4-[3-(2-Benzoy chloro-phenoxy) butoxy]-2-methy phenylsulfanyl} acid  79  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-propion	-acetic	phenylsulfanyl}-acetic	H ₃ C S O	
CH ₃ CH ₃ CH ₃ chloro-phenoxy) butoxy]-2-methy phenylsulfanyl acid  79  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-propion	•	acid	H ₃ C CH ₃ OH	
CH ₃ CH ₃ CH ₃ chloro-phenoxy) butoxy]-2-methy phenylsulfanyl acid  79  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-methyl)-phenox butoxy}-2-methyl)-propion				,
Description of the control of the co	yl-4-	{4-[3-(2-Benzoyl-4-		78
Phenylsulfanyl acid  79  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-meth phenyl)-propion	)-	chloro-phenoxy)-		:
Phenylsulfanyl acid  79  3-(4-{3-[4-Ethyl (hydroxy-pheny methyl)-phenox butoxy}-2-meth phenyl)-propion	yl-	butoxy]-2-methyl-	CH CH	
3-(4-{3-[4-Ethyle (hydroxy-pheny methyl)-phenox butoxy}-2-meth phenyl)-propion	-acetic	phenylsulfanyl}-acetic		
H ₃ C (hydroxy-pheny methyl)-phenox butoxy}-2-meth phenyl)-propion		acid	CH ₃	
H ₃ C CH ₃ methyl)-phenox butoxy}-2-meth phenyl)-propion	1-2-	3-(4-{3-[4-Ethyl-2-		79
H ₃ C butoxy}-2-meth	<b>1</b> -	(hydroxy-phenyl-		
butoxy}-2-meth	y}-	methyl)-phenoxy]-	/ CH	
CH ₂ \ \ \ \ \ \ \ \ \ pnenyi)-propion	yl-	butoxy}-2-methyl-		
ОН	nic acid	phenyl)-propionic acid	CH. V	
			OH	
		3-(4-{3-[4-Ethyl-2-		80
		(hydroxyimino-phenyl-		
HC /= / Incury!) phonox.		methyl)-phenoxy]-	/ CH _a	
butoxy}-2-metn		butoxy}-2-methyl-		
CH ₃ OH phenyl)-propion	ic acid	phenyl)-propionic acid	CH ₃ OH	

No.	Structure	<u>Name</u>
81		3-(4-{3-[4-Ethyl-2-
·		(methoxyimino-phenyl-
	H ₃ C CH ₃	methyl)-phenoxy]-
		butoxy}-2-methyl-
	ĊH ₃ ОН	phenyl)-propionic acid
82	H ₃ C CH ₃ Chira	3-{4-[3-(4-Isopropyl-2-
ω	H ₃ C O	phenoxy-phenoxy)-
	O CH ₃ OH	butoxy]-2-methyl-
		phenyl}-propionic acid
		·
83	Chiral	{4-[3-(4-Isopropyl-2-
		phenoxy-phenoxy)-
	H³C´ — CH³	butoxy]-2-methyl-
	H ₃ C S, ,o	phenylsulfanyl}-acetic
	н₃с	acid
0.4	ОН	0 (4 50 (4 7) 1 0
84	H₃C CH₃	3-{4-[3-(4-Ethyl-2-
	H ₃ C CH ₃	isobutyryl-phenoxy)-
		butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
	у у	
85		3-{4-[3-(2-
, *	<b>&gt;</b> 0	Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	CH ₃ OH	propionic acid
86	$\triangleleft$	3-{4-[3-(2-
	<b>)</b>	Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
·		2-methyl-phenyl}-
	ČH₃ OH	propionic acid

No.	Structure	<u>Name</u>
87		3-{4-[3-(2-
	$\vdash$	Cyclopentanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	н _з с	propionic acid
	ОН	
88	H ₃ C CH ₃	2-{4-[3-(4-Ethyl-2-
	H ₃ C	isobutyryl-phenoxy)-
	OH OH	butoxy]-phenoxy}-2-
	CH ₃ H ₃ C´ CH ₃	methyl-propionic acid
89		2-{4-[3-(2-
	<b>)</b> =0	Cyclopropanecarbonyl-4-
•	H ₃ C	ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	CH ₃ H ₃ C CH ₃ OH	propionic acid
90	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	O CH3 OH	butoxy]-2-methyl-
		phenyl}-propionic acid
		(4.50.00 P. 1.5
91		{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
·	H ₃ C CH ₃	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	, ch³ — Он	acid
92	Chiral	3-{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	CH₃	butoxy]-2-methyl-
	CI—( )	phenyl}-propionic acid
	CH ₃	
	ОН	

No.	Structure	<u>Name</u>
93	Chiral	{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	,CH₃	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	CH ₃	acid
	ОН	,
94	Chiral	3-{4-[3-(3-Benzoyl-5-
*		trifluoromethyl-pyridin-
	F. CH ₃	2-yloxy)-butoxy]-2-
	F NO NO	methyl-phenyl}-
	Ĉн ₃ ОН	propionic acid
95	Chiral	{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-2-
	F CH ₃	methyl-phenylsulfanyl}-
	F H ₃ C OH	acetic acid
96	Chiral	3-{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-
	,cH³	yloxy)-butoxy]-2-
	CI—CI—O	methyl-phenyl}-
	CH ₃ OH	propionic acid
97	Chiral	3-{4-[3-(5-Chloro-3-
	<b>&gt;=</b> /	phenoxy-pyridin-2-
	, CH₃	yloxy)-butoxy]-2-ethyl-
	CI—O	phenyl}-propionic acid
	CH ₃ OH	

acetic acid  99  F  OH  Chiral  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  100  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  101  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  F  OH  Acetic acid  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  F  OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-	No.	Structure	Name
Properties and the second of t	98	Chiral	{4-[3-(5-Chloro-3-
methyl-phenylsulfanyl}-acetic acid  99  F  OH  OH  OH  OH  OH  OH  OH  OH  OH		<del>-</del>	phenoxy-pyridin-2-
Phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxyl- phenyl}-propionic acid  102    F		CH₃ CH₃	yloxy)-butoxy]-2-
99  F  OH  Chiral  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  100  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  101  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  F  OH  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  T  OH  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  T  T  T  T  T  T  T  T  T  T  T  T  T			methyl-phenylsulfanyl}-
phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  100  Chiral 3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  101  Chiral 3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  A  3-{2-Methyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  T CH ₃ S OH  A  3-{2-Methyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-propoxy]-  CH ₃ T CH ₃		<b>,</b>	acetic acid
phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  100  Chiral 3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  101  Chiral 3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  A  Chiral 3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  T OH  A  CH3  CH3  A  CH4  A  CH4  A  CH3  CH3  CH3  CH3  CH4  A  CH4  CH3  CH3  Phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-propoxy]-	99	F CH ₃ Chiral	3-{2-Methyl-4-[3-(3-
trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  100  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  T OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-propoxy]-  T T T T T T T T T T T T T T T T T T			12.
phenyl}-propionic acid  100  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  101  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		O CH ₃ OH	
Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid			2-yloxy)-butoxy]-
phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  101  Chiral  3-{2-Ethyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-propionic acid  3-{2-Methyl-4-[3-(3- phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-propoxy]-			phenyl}-propionic acid
trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  101  Chiral  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin- 2-yloxy)-propoxy]-	100	Chiral	3-{2-Ethyl-4-[3-(3-
2-yloxy)-butoxy]- phenyl}-propionic acid  101  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-  CH ₃ phenoxy-5- trifluoromethyl-pyridin-2-yloxy)-propoxy]-		<b>&gt;</b>	phenoxy-5-
phenyl}-propionic acid  Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102 F OH 3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		F. CH ₃	trifluoromethyl-pyridin-
Chiral 3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid  102 F OH  3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		F	2-yloxy)-butoxy]-
phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		H ₃ C OH	phenyl}-propionic acid
trifluoromethyl-pyridin- 2-yloxy)-butoxy]- phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-	101	Chiral	3-{2-Ethyl-4-[3-(3-
Propionic acid  2-yloxy)-butoxy]- phenyl}-propionic acid  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-			phenoxy-5-
Phenyl}-propionic acid  102  F OH  3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		F, CH ₃	trifluoromethyl-pyridin-
102 F OH 3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-		F N H C O	2-yloxy)-butoxy]-
PF OH  CH3  Phenoxy-5- trifluoromethyl-pyridin- 2-yloxy)-propoxy]-			phenyl}-propionic acid
trifluoromethyl-pyridin- 2-yloxy)-propoxy]-	102	- F 0	3-{2-Methyl-4-[3-(3-
F CH ₃ trifluoromethyl-pyridin- 2-yloxy)-propoxy]-		F OH	phenoxy-5-
			trifluoromethyl-pyridin-
when vill manipulation and	·		2-yloxy)-propoxy]-
	-		phenyl}-propionic acid
OH (trifluoroacetic acid salt)		ОН	(trifluoroacetic acid salt)

No.	Structure	Name
103	F\$ 0	3-{4-[3-(5-Chloro-3-
	F OH	phenoxy-pyridin-2-
		yloxy)-propoxy]-2-
	CH₃	methyl-phenyl}-
	CI—CI—CI—CI—CI—CI—CI—CI—CI—CI—CI—CI—CI—C	propionic acid
	—N OH	
104		3-{4-[2-(5-Chloro-3-
		phenoxy-pyridin-2-
	,o´	ylamino)-ethoxy]-2-
	CI—N CH ₃	methyl-phenyl}-
		propionic acid
	ОН	rr
105	H ₃ C /=N CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
· y	ОН	propoxy]-2-methyl-
		phenyl}-propionic acid
106	Chiral	3-{2-Methyl-4-[3-(6-
		methyl-2-phenoxy-
	N=< CH³	pyridin-3-yloxy)-
	H ₃ C—O	butoxy]-phenyl}-
	н₃с*	propionic acid
107		3-{4-[3-(5-Ethyl-
		biphenyl-2-yloxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
	ОН	1
108	Chiral	3-{4-[3-(4-Ethyl-2-
	ÇH₃ O	oxazol-2-yl-phenoxy)-
	H ₃ C OH	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid

No.	Structure	Name
109	H ₃ C Chiral	3-{4-[3-(4-Ethyl-2-
		thiazol-4-yl-phenoxy)-
	N CH₃ OH	butoxy]-2-methyl-
	s .	phenyl}-propionic acid
110	Chiral	3-{4-[3-(4-Ethyl-2-
	)=N	pyridin-2-yl-phenoxy)-
-	H ₃ C CH ₃	butoxy]-2-methyl-
-	H ₃ C OH	phenyl}-propionic acid
111	Chiral	{4-[3-(4-Ethyl-2-pyridin-
	V ÇH₃ 0	2-yl-phenoxy)-butoxy]-
	H ₃ C OH	2-methyl-
		phenylsulfanyl}-acetic
	H₃C̄	acid
112	ÇH ₃ Chiral	3-{2-Ethyl-4-[3-(4-ethyl-
·	ОН	2-pyridin-2-yl-phenoxy)-
·		butoxy]-phenyl}-
	CH ₃	propionic acid
113	Chiral	3-{4-[3-(4-Chloro-2-
	CH³	pyridin-2-yl-phenoxy)-
	CI—()—O	butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	он	
114	F CH ₃ Chiral	3-{2-Methyl-4-[3-(2-
·	F OH	pyridin-2-yl-4-
		trifluoromethyl-
	СH ₃	phenoxy)-butoxy]-
		phenyl}-propionic acid

No.	Structure	Name
115	H ₃ C O Chiral	3-{2-Ethyl-4-[3-(2-
·	F OH	pyridin-2-yl-4-
		trifluoromethyl-
	CH₃	phenoxy)-butoxy]-
*.		phenyl}-propionic acid
116	Chiral	3-{4-[3-(4-Ethyl-2-
• • .	H₃C, CH.	pyridin-3-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C C	phenyl}-propionic acid
*	ОН	· .
117	Chiral	3-{4-[3-(4-Chloro-2-
	CH₃	pyridin-3-yl-phenoxy)-
	ci—()—o	butoxy]-2-methyl-
	ČH ₃	phenyl}-propionic acid
118	Chiral	3-{4-[3-(4-Ethyl-2-
	H ₃ C, CH	pyridin-4-yl-phenoxy)-
	CH ₃	butoxy]-2-methyl-
7 9	H ₃ C O	phenyl}-propionic acid
-	ОН	*
119	F Chiral	3-{2-Methyl-4-[3-(2-
	г г	pyridin-4-yl-4-
		trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-
		phenyl}-propionic acid
120	F N H ₃ C O Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-4-yl-4-
		trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-
		phenyl}-propionic acid

Structure	Name
CI CH ₃ Chiral	3-{4-[3-(2- Benzo[d]isoxazol-3-yl-4-
OH OH	chloro-phenoxy)-
	butoxy]-2-methyl-
CH ₃	phenyl}-propionic acid
Chiral	(R)-{4-[3-(4-ethyl-2-
	phenoxy-phenoxy)-
O CH₃	butoxy]-2-methyl-
	phenylsulfanyl}-acetic
CH₃ OH	acid
Chiral	(R)-{4-[3-(2-benzoyl-4-
	methyl-phenoxy)-
CH ₃	butoxy]-2-methyl-
$H_3C \longrightarrow O \longrightarrow S \bigcirc O$	phenylsulfanyl}-acetic
С́н _з Он	acid
Chiral	(R)-{4-[3-(2-benzoyl-4-
	trifluoromethoxy-
F—————————————————————————————————————	phenoxy)-butoxy]-2-
FO	methyl-phenylsulfanyl}-
CH ₃ OH	acetic acid
	{4-[3-(2-benzoyl-4-ethyl-
	phenoxy)-hexyloxy]-2-
H ₂ C CH ₃	methyl-phenylsulfanyl}-
	acetic acid
ОН	*
СН ₃	
	CH ₃ CH ₃ Chiral  Chiral  Chiral  Chiral  Chiral  Chiral  CH ₃ CH ₃ CH ₃ CH ₃ Chiral  Chiral  Chiral  Chiral  Chiral  CH ₃ CH

No.	Structure	Name
126		3-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-
	)=0 CH₃	hexyloxy]-2-methyl-
-	H ₃ C 0 0 0	phenyl}-propionic acid
	ОН	×
:	CH ₃	
127	Chiral	(R)-3-{4-[3-(4-ethyl-2-
		phenoxy-phenoxy)-
	$H_3C$ $\nearrow$ $CH_3$	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH ₃ OH	
128	Chiral	(R)-3-(4-{3-[4-ethyl-2-
		(1-phenyl-vinyl)-
	CH ₂ CH ₃	phenoxy]-butoxy}-2-
*	H ₃ C 0 0	methyl-phenyl)-
	CH ₃ OH	propionic acid
129	Chiral	(R)-3-(4-{3-[4-ethyl-2-
	CH ₃	(1-methyl-1-phenyl-
	$H_3C$ $CH_3$ $CH_3$ $CH_3$	ethyl)-phenoxy]-
		butoxy}-2-methyl-
	CH₃ OH	phenyl)-propionic acid
130	Chiral	(R)-3-{4-[3-(2-benzoyl-
		4-methyl-phenoxy)-
	)=o ,CH₃	butoxy]-2-methyl-
·	$H_3C$ $O$ $O$	phenyl}-propionic acid
	CH₃ OH	

No.	Structure	<u>Name</u>
131	Chiral	(R)-3-(4-{3-[4-ethyl-2-
		(1-phenyl-ethyl)-
	CH ₃	phenoxy]-butoxy}-2-
	H ₃ C 0 0	methyl-phenyl)-
	CH ₃ OH	propionic acid
132	Chiral	(R)-3-(4-{3-[4-ethyl-2-
	l i	(pyridine-2-carbonyl)-
	CH₃	phenoxy]-butoxy}-2-
	H ₃ C 0 0	methyl-phenyl)-
	CH ₃ OH	propionic acid
133		3-(2-methyl-4-{3-[2-
		(thiophene-2-carbonyl)-
= .	F CH ₃	4-trifluoromethoxy-
	f 0-{ }-0 \	phenoxy]-butoxy}-
	ĊН ₃ ОН	phenyl)-propionic acid
134		3-(4-{3-[4-ethyl-2-
	<b>∀</b> ³	(thiophene-2-carbonyl)-
	CH ₃	phenoxy]-butoxy}-2-
	H ₃ C 0 0 0	methyl-phenyl)-
	CH₃ OH	propionic acid
135		3-(4-{3-[4-ethyl-2-
		(naphthalene-1-
÷	CH ₃	carbonyl)-phenoxy]-
	H ₃ C 0 0	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid

No.	Structure	<u>Name</u>
136		3-(4-{3-[4-ethyl-2-(1-
		phenyl-vinyl)-phenoxy]-
	CH ₂ CH ₃	butoxy}-2-methyl-
	H ₃ C	phenyl)-propionic acid
	CH ₃ OH	
137		3-{4-[3-(2-benzoyl-
		phenoxy)-butoxy]-2-
	)=o ,cн₃	methyl-phenyl}-
		propionic acid
	CH ₃ OH	*
138		3-{4-[3-(2-benzoyl-4-
		methyl-phenoxy)-
	)=o ,CH₃	butoxy]-2-methyl-
	H ₃ C-\(\bigc\) 0 \(\circ\) 0	phenyl}-propionic acid
	CH₃ OH	
139		3-{4-[3-(2-benzyl-4-
		ethyl-phenoxy)-butoxy]-
	CH₃	2-methyl-phenyl}-
	H ₃ C	propionic acid
	CH ₃ OH	
140		3-{4-[3-(2-benzoyl-4-
		bromo-phenoxy)-
	)=o ,CH₃	butoxy]-2-methyl-
	$Br \longrightarrow O \longrightarrow O \longrightarrow O$	phenyl}-propionic acid
	CH₃ OH	

No.	Structure	Name
141		3-{4-[3-(2-benzoyl-4-
·		butyl-phenoxy)-butoxy]-
	$H_3C$ $\longrightarrow$ $O$ $CH_3$	2-methyl-phenyl}-
		propionic acid
	CH ₃ OH	
	CH ₃ OH	
142		3-{4-[3-(2-benzoyl-4-
		propyl-phenoxy)-
	H ₃ C— CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH₃ OH	
143		3-{4-[4-(2-benzoyl-4-
	ÇH₃ Q	ethyl-phenoxy)-1-
	СН3 СН3 ОН	methyl-butoxy]-2-
		methyl-phenyl}-
	H³C	propionic acid
144		3-{4-[4-(2-benzoyl-4-
	ÇH₃ Q	ethyl-phenoxy)-
	OH OH	pentyloxy]-2-methyl-
		phenyl}-propionic acid
• .	H ₃ C CH ₃	8 (8)
145		3-{4-[3-(2-benzoyl-4-
145		ethyl-phenoxy)-2-
	CH ₃	methyl-propoxy]-2-
	H ₃ C /= CH ₃ /= 3	methyl-phenyl}-
		propionic acid
	ОН	proprome acid
146		3-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-
	PO CH³	propoxy]-2-methyl-
	H ₃ C 0 0	phenyl}-propionic acid
	ОН	*

No.	Structure	<u>Name</u>
147	H ₃ C CH ₃	3-(4-{3-[4-ethyl-2-(4-fluoro-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
148	ОН	3-(4-{3-[4-ethyl-2-(2-trifluoromethyl-benzoyl)-
	H ₃ C CH ₃ O OH	phenoxy]-propoxy}-2- methyl-phenyl)- propionic acid
149	F F O O O O O O O O O O	3-(4-{3-[4-ethyl-2-(3-trifluoromethyl-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
150	H ₃ C CH ₃ O OH	3-(4-{3-[4-ethyl-2- (thiophene-2-carbonyl)- phenoxy]-propoxy}-2- methyl-phenyl)- propionic acid
151	H ₃ C CH ₃ OH	3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	<u>Name</u>
152		3-(4-{3-[4-ethyl-2- (naphthalene-1-
	H ₃ C CH ₃	carbonyl)-phenoxy]- propoxy}-2-methyl-
	ОН	phenyl)-propionic acid
153		3-(4-{3-[4-ethyl-2-(1-
. ;	CH ₂ CH ₃	phenyl-vinyl)-phenoxy]- propoxy}-2-methyl-
. *	H ₃ C O O O	phenyl)-propionic acid
	ОН	*
154		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]-
	H ₃ C, -0	phenoxy}-2-methyl-
	H ₃ C O	propionic acid
	H₃C → O H₃C → O HO	
155		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-2-
,	0	methyl-propoxy]-
	H ₃ C CH ₃	phenoxy}-2-methyl-
		propionic acid
	H ₃ C O H ₃ C O HO	
	ΠO	

No.	Structure	Name
156		2-{4-[3-(2-benzyl-4-
		ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	H ₃ C O	propionic acid
	H ₃ Ć	
	H³C $\swarrow$	· .
	H₃C´ →O HO	
157		2-{4-[3-(2-benzoyl-4-
		bromo-phenoxy)-
		butoxy]-phenoxy}-2-
	Br	methyl-propionic acid
	H ₃ Ć	meuryi-propionie acid
	H₃C H₃C →O	,
	" но́	
158	0	2-{4-[3-(2-benzoyl-4-
		butyl-phenoxy)-butoxy]-
	H ₃ C	phenoxy}-2-methyl-
	H ₃ C	propionic acid
	н ₃ С 0 н ₃ С 0	
	H₃C )= ^O HO	
150	Chiral	(D) 2 (4 [2 (4 shlars 2
159	( )	(R)- 3-{4-[3-(4-chloro-2-
	O CH ₃	phenoxy-phenoxy)- butoxy]-2-methyl-
		phenyl}-propionic acid
	CH ₃ OH	

No.	Structure	Name
160	Chiral	(R)-3-{2-methyl-4-[3-(2-
		phenoxy-4-
	O CH₃	trifluoromethyl-
		phenoxy)-butoxy]-
	ÇH₃ OH	phenyl}-propionic acid
161	Chiral	(R)-3-{2-methyl-4-[3-(2-
		phenoxy-4-
	F O CH ₃	trifluoromethoxy-
	FO	phenoxy)-butoxy]-
	CH ₃ OH	phenyl}-propionic acid
162	Chiral	(R)-3-{2-methyl-4-[3-(4-
		methyl-2-phenoxy-
	O CH₃	phenoxy)-butoxy]-
	H3C-(O	phenyl}-propionic acid
	_С н³ , Он	
163	Chiral	(R)-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
	O CH ₃	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	CH₃ 'OH	acid
164		3-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
	Ò СН₃ ∕=<	propoxy]-2-methyl-
		phenyl}-propionic acid
	ОН	
165	Chiral	(R)-3-{4-[3-(2-
	ş	benzo[b]thiophen-3-yl-4-
	CH₃	chloro-phenoxy)-
	cı—()o	butoxy]-2-methyl-
	CH ₃ OH	phenyl}-propionic acid
<u> </u>		

No.	Structure	<u>Name</u>
166	Chiral	(R)- 3-{4-[3-(4-chloro-2-
	ÇH ₃	pyridin-3-yl-phenoxy)-
		butoxy]-2-methyl-
	CH ₃ OH	phenyl}-propionic acid
167	Chiral	(R)-3-{4-[3-(4-chloro-2-
:		phenoxy-phenoxy)-
		butoxy]-phenyl}-2,2-
er.		difluoro-propionic acid
*	CH ₃ F OH	
168	Chiral	%)(R)-3-{3-bromo-4-[3-
		(4-chloro-2-phenoxy-
	O Br	phenoxy)-butoxy]-
*		phenyl}-propionic acid
0	ĊH₃ OH	
169	Chiral	(R)-3-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
	O H ₃ C	butoxy]-3-methyl-
:		phenyl}-propionic acid
	ČH₃ OH	*
170	Chiral	(R)-{3-bromo-4-[3-(4-
		chloro-2-phenoxy-
	O Br	phenoxy)-butoxy]-
	$CI \longrightarrow O \longrightarrow O \longrightarrow O$	phenyl}-acetic acid
	CH ₃ HO	
171	F Chiral	(R)-3-{4-[3-(4-bromo-2-
	, CH ₃	trifluoromethoxy-
	Br— 0, 0	phenoxy)-butoxy]-2-
		methyl-phenyl}-
	CH ₃ OH	propionic acid

No.	Structure	Name
172	Chiral  Cl  CH ₃	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-3-methyl-phenyl}-acetic acid
173	CI—O CH ₃ HOOO	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-acetic acid
174	CI CH ₃ Chiral OH	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-trifluoromethyl-phenyl}-propionic acid
175	$CI \longrightarrow CH_3$ $CH_3$ $CH_3$ $O$ $CH_3$ $O$ $O$ $O$ $O$ $O$ $O$	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
176	$\begin{array}{c} CH_3 \\ CH_3 \\ CH_3 \\ \end{array} \begin{array}{c} CH_3 \\ OH \\ \end{array}$	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid

No.	Structure	<u>Name</u>
177	CI O Chiral	(R)-3-{2-Chloro-4-[3-(4-
	CI OH	chloro-2-phenoxy-
		phenoxy)-butoxy]-
		phenyl}-propionic acid
		н:
178	F O Chiral	(R)-3-{4-[3-(4-Chloro-2-
	ОН	phenoxy-phenoxy)-
		butoxy]-2-fluoro-
		phenyl}-propionic acid
179	Chiral	(R)-3-{4-[3-(4-Chloro-2-
	CI	phenoxy-phenoxy)-
		butoxy]-2-ethyl-phenyl}-
		propionic acid
180	CI O Chiral	(R)-3-{4-[3-(2-Benzoyl-
	OH OH	4-ethyl-phenoxy)-
· .		butoxy]-2-chloro-
		phenyl}-propionic acid
181	F O Chiral	(R)-3-{4-[3-(2-Benzoyl-
	OH	4-ethyl-phenoxy)-
		butoxy]-2-fluoro-
		phenyl}-propionic acid
		phonyi propionie uoid
182	O Chiral	(R)-3-{4-[3-(4-Chloro-2-
	CIOH	phenoxy-phenoxy)-
	<b>∀</b> °°~°	butoxy]-phenyl}-
		propionic acid
	<u> </u>	

No.	Structure	Name
183	O Chiral	(R)-3-{4-[3-(2-Benzoyl-
	ОН	4-ethyl-phenoxy)-
		butoxy]-phenyl}-
		propionic acid
	<u> </u>	
184	Cl. Chiral	(R)-3-{4-[3-(4-Chloro-2-
	I II I I I I I I I I I I I I I I I I I	phenoxy-phenoxy)-
		pentyloxy]-2-methyl-
	Isomer 1	phenyl}-propionic acid
105		(D) 2 (A [2 (2 D ]
185	O Chiral OH	(R)-3-{4-[3-(2-Benzoyl-
=		4-ethyl-phenoxy)-
		pentyloxy]-2-methyl-
	Isomer 1	phenyl}-propionic acid
186	Chiral	(R)-{4-[3-(3-Benzoyl-
100 .	, s, l	naphthalen-2-yloxy)-
	OH OH	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
		acid
107	Obited.	
187	Chiral	(R)-3-{4-[3-(3-Benzoyl-
	OH OH	naphthalen-2-yloxy)-
		butoxy]-2-methyl-
		phenyl}-propionic acid
100	<u> </u>	(D) 2 (4 [2 (4 E4 12
188	O Chiral OH	(R)-3-{4-[3-(4-Ethyl-2-
		phenoxy-phenoxy)-
		butylsulfanyl]-2-methyl-
		phenyl}-propionic acid
L		

No.	Structure	<u>Name</u>
189	O Chiral	(R)-3-{4-[3-(4-Isopropyl-
	ОН	2-phenoxy-phenoxy)-
		butylsulfanyl]-2-methyl-
*		phenyl}-propionic acid
190	Chiral	(R)-3-{4-[3-(4-Chloro-2-
:		phenoxy-phenoxy)-
	ОН	butoxy]-2-propyl-
•		phenyl}-propionic acid
·		×
101		(D) (4 f2 (4 C))
191	Chiral	(R)-{4-[3-(4-Chloro-2-
•	OH S	phenoxy-phenoxy)-
		butoxy]-2-ethyl-
100		phenylsulfanyl}-acetic
		acid
192	CI Chiral	(R)-3-{4-[3-(2-Benzoyl-
	OH OH	4,5-dichloro-phenoxy)-
		butoxy]-2-methyl-
		phenyl}-propionic acid
100		(D) 0 (0 ) ( 1 1 4 50 (0
193	CF ₃ O Chiral	(R)-3-{2-Methyl-4-[3-(2-
		phenoxy-4-
		trifluoromethyl-
		phenoxy)-butylsulfanyl]-
		phenyl}-propionic acid
194	O Chiral	(R)-3-{2-Ethyl-4-[3-(4-
	ОН	ethyl-2-phenoxy-
		phenoxy)-butoxy]-
		phenyl}-propionic acid

CF ₃ OH pheno trifluo pheno	-{2-Ethyl-4-[3-(2-oxy-4-oromethyl-oxy)-butoxy]-
CF ₃ OH pheno trifluo pheno	oromethyl- oxy)-butoxy]-
pheno	oxy)-butoxy]-
	•
nheny	yl}-propionic acid
Priori	
196 Chiral (R)-3	-{4-[3-(2-Benzoyl-
OH 4-eth	yl-phenoxy)-
butox	(y]-2-ethyl-phenyl}-
propi	onic acid
1 9	-{2-Ethyl-4-[1-
CF ₃ OH meth	yl-3-(2-phenoxy-4-
triflue	oromethyl-
pheno	oxy)-propoxy]-
pheny	yl}-propionic acid
198   O Chiral (R)-3	-{2-Methyl-4-[1-
OH meth	yl-3-(2-phenoxy-4-
triflu	oromethoxy-
pheno	oxy)-
propy	ylsulfanyl]-phenyl}-
propi	onic acid
199 Chiral (S)-3	-{4-[3-(4-Chloro-2-
Ci OH pheno	oxy-phenoxy)-
	(y]-2-ethyl-phenyl}-
propi	onic acid
200 3-{4-	[3-(4-Chloro-2-
CI OH pheno	oxy-phenoxy)-
propo	oxy]-2-ethyl-
pheny	yl}-propionic acid

Chiral (R)-3-{4-[3-(2,4-Diphenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid  202 Cl Cl Cl Cl Chiral (R, S)-2-thyl-phenyl)-3-methyl-butoxy]-2-methyl-phenyl}-cyclopropanecarboxylic acid  203 (R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-2-methyl-phenoxy]-2-methyl-phenoxy]-2-methyl-propionic acid  204  205  F F CH ₃ CH	No.	Structure	<u>Name</u>
Diphenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid  202  Clase Isomer 2  Cise Isomer 2  C	201	O Chiral	(R)-3-{4-[3-(2,4-
propionic acid  202  Cl		ОН	Diphenoxy-phenoxy)-
202  Cl OH OH OH  2-{4-[4-(4-Chloro-2-phenoxy-phenyl)-3-methyl-butoxy]-2-methyl-phenyl}-cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy]-2-methyl-propionic acid  (R, S)-2-methyl-phenoxy]-2-methyl-propionic acid  204  204  205  CH ₃ C			butoxy]-2-ethyl-phenyl}-
phenoxy-phenyl)-3- methyl-butoxy]-2- methyl-phenyl}- cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl- 2-phenylsulfanyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-2-methyl-	ė.		propionic acid
phenoxy-phenyl)-3- methyl-butoxy]-2- methyl-phenyl}- cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl- 2-phenylsulfanyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-2-methyl-			
methyl-butoxy]-2- methyl-phenyl}- cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl- 2-phenylsulfanyl- phenoxy}-2-methyl- propionic acid  204  204  205  Age of the characteristic of the content of the content of the cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl- 2-phenylsulfanyl- phenoxy}-2-methyl- phenoxy)-butoxy]- 2-methyl-phenoxy)-butoxy]- 2-methyl-propionic acid (enamtiomer pair 1)  205  Age of the characteristic of the cyclopropylmethyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-2-methyl- phenoxy)-2-methyl-	202	O Chiral	2-{4-[4-(4-Chloro-2-
Cis - Isomer 2  methyl-phenyl}- cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl- 2-phenylsulfanyl- phenoxy)-butoxy]- phenoxy}-2-methyl- propionic acid  204  205  F  CH ₃		СІ	phenoxy-phenyl)-3-
cyclopropanecarboxylic acid  (R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy]-butoxy]-phenoxy}-2-methyl-propionic acid  204  205  F  CH ₃ C			methyl-butoxy]-2-
203  H ₃ C  CH ₃		Cis - Isomer 2	methyl-phenyl}-
204  H ₃ C  Cyclopropylmethyl-4-  trifluoromethyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy]-2-methyl-			cyclopropanecarboxylic
2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-phenoxy)-butoxy]-phenoxy}-2-methyl-phenoxy)-butoxy]-2-methyl-phenoxy)-butoxy]-2-methyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-2-methyl-propionic acid (enamtiomer pair 1)  205    F			acid
phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy]-2-methyl- propionic acid  2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl- phenoxy)-butoxy]- 2-methyl- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy)-butoxy]- phenoxy]-2-methyl-	203		(R, S)-2-{4-[3-(4-Ethyl-
204  204  204  205  Phenoxy-2-methyl-propionic acid  2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy)-butoxyl-phenoxyl-2-methyl-phenoxyl-2-methyl-propionic acid (enamtiomer pair 1)  205  Propionic acid (enamtiomer pair 1)  (R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methy			2-phenylsulfanyl-
204  204  2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxyl-butoxyl-phenoxyl-chair filluoromethyl-phenoxyl-butoxyl-phenoxyl-butoxyl-phenoxyl-butoxyl-phenoxyl-butoxyl-phenoxyl-butoxyl-phenoxyl-butoxyl-phenoxyl-2-methyl-phenoxyl-butoxyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-2-methyl-phenoxyl-butoxyl-phenoxyl-2-methyl-			phenoxy)-butoxy]-
204  2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-2-methyl-propionic acid (enamtiomer pair 1)  205  F  CH ₃ CH			phenoxy}-2-methyl-
Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]- 2-methyl-propionic acid (enamtiomer pair 1)  205  F  CH ₃ H ₃ C  CH ₃			propionic acid
Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]- 2-methyl-propionic acid (enamtiomer pair 1)  205  F  CH ₃ H ₃ C  CH ₃			
phenoxy)-butoxy]- 2-methyl- phenylsulfanyl}-2- methyl-propionic acid (enamtiomer pair 1)  205  CH ₃	204		2-{4-[3-(R,S-2-
phenoxy)-butoxy]- 2-methyl- phenylsulfanyl}-2- methyl-propionic acid (enamtiomer pair 1)  205  F  CH ₃ CH	or .	CH ₂ O	Benzenesulfinyl-4-ethyl-
2-methyl-phenylsulfanyl}-2-methyl-propionic acid (enamtiomer pair 1)  205  (R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-			phenoxy)-butoxy]-
methyl-propionic acid (enamtiomer pair 1)  (R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-		1'3	2-methyl-
(enamtiomer pair 1)  (enamtiomer pair 1)  (R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-			phenylsulfanyl}-2-
205  F  CH ₃ CH ₃ CH ₃ (R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-		*	methyl-propionic acid
Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]- phenoxy}-2-methyl-			(enamtiomer pair 1)
Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]- phenoxy}-2-methyl-			
Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]- phenoxy}-2-methyl-	205	F O H.C II	(R, S)-2-{4-[3-(2-
phenoxy)-butoxy]- phenoxy}-2-methyl-			Cyclopropylmethyl-4-
phenoxy}-2-methyl-		CH ₃	trifluoromethyl-
			phenoxy)-butoxy]-
propionic acid		$\checkmark$	phenoxy}-2-methyl-
	·		propionic acid
1			

No.	Structure	Name
206		(R, S)-2-Methyl-2-{4-[3-
	H³C	(2-methyl-3-phenyl-7-
	СН³ СН³ ОН	propyl-
	H ₃ C CH ₃	benzofuran-6-yloxy)-
	*	butoxy]-phenoxy}-
	│ │    CH₃	propionic acid
207		(R, S)-2-Methyl-2-{4-[3-
	CH3 H3C	(4-methyl-3-phenyl-7-
	ÇН₃ СОЗ ОН	propyl-
	CH ₃	benzofuran-6-yloxy)-
		butoxy]-phenoxy}-
	I СН _з	propionic acid
		н.
208	$\nabla$	(R, S)-2-{4-[3-(2-
	F CH ₃ H ₃ C	Cyclopropylmethyl-4-
	F CH ₃ OH	trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-2-
		methyl-phenoxy}-2-
		methyl-propionic
		acid
·		
209	- 🗸 🗸	(R, S)-3-{4-[3-(2-
	FF CH ₃ O	Cyclopropylmethyl-4-
	F CH ₃ OH	trifluoromethyl-
		phenoxy)-butoxy]-2-
		methyl-phenyl}-
		propionic acid
		i) .
		L

No.	Structure	Name
210	H ₃ C CH ₃ OH	3-{R-4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
211	H ₃ C CH ₃ OH	3-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid isomer 2
212	H ₃ C CH ₃ H ₃ C OH CH ₃	(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
213	$H_3C$ $CH_3$ $CH_3$ $OH$	(R, S)-3-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
214	$H_3C$ $CH_3$ $CH_3$ $CH_3$ $CH_3$ $CH_3$ $CH_3$	(R, S)-2-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy) -butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid

No.	Structure	<u>Name</u>
215	H ₃ C CH ₃ OH	(R, S)-3-{4-[3-(2-Benzenesulfonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
216	FFF CH ₃ OH	3-{4-[3-(2-Benzoyl-4-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

30. (Original). The compound of Claim 29, wherein the compound is

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 31. (Currently Amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claims 1-30-Claim 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  - 32. (Currently Amended). A pharmaceutical composition comprising:
- (1) a compound of <u>Claims 1 30 Claim 1</u>, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof;
- (2) a second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising

agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and

- (3) optionally a pharmaceutically acceptable carrier.
- 33. (Canceled).
- 34. (Canceled).
- 35. (Canceled).
- 36. (Canceled).
- 37. (Canceled).
- 38. (Canceled).
- 39. (Canceled).
- 40. (Canceled).
- 41. (Canceled).
- 42. (Canceled).
- 43. (Currently Amended). A method for lowering blood-glucose in a mammal <u>in need thereof</u> comprising the step of administering an effective amount of a compound of <u>Claims 1 30 Claim 1</u>.
- 44. (Currently Amended). A method of treating or preventing disease or condition in a mammal <u>in need thereof</u> selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of <u>Claims 1-30 Claim 1</u>.
- 45. (Currently Amended). A method of treating or preventing diabetes mellitus in a mammal <u>in need there of comprising</u> the step of administering to a mammal a therapeutically effective amount of a compound of <u>Claims 1 30 Claim 1</u>.
- 46. (Currently Amended). A method of treating or preventing cardiovascular disease in a mammal <u>in need thereof</u> comprising the step of administering to a

## Docket No. X-15998

mammal a therapeutically effective amount of a compound of <u>Claims 1-30 Claim 1</u>, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

- 47. (Canceled).
- 48. (Currently Amended). A method of treating or preventing disease or condition in a mammal <u>in need thereof</u> selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of <u>Claims 1 30 Claim 1</u> and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.
  - 49. (Canceled)